Condition
Gout; Hyperuricemia
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (3)
Trial Status
Completed3
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07061587Not ApplicableNot Yet RecruitingPrimary
Developing A Gout Action Plan in Primary Care Setting in Singapore
NCT03857165Phase 1CompletedPrimary
Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients
NCT02890966Phase 1CompletedPrimary
Multiple Dose Study of SHR4640 in Healthy Subjects
NCT02815839Phase 1CompletedPrimary
Single Dose Study of SHR4640 in Healthy Subjects
Showing all 4 trials